Trial Profile

AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Mar 2023 According to a Hepion Pharmaceuticals media release, the company participate in American Chemical Society and the Joseph Priestley Society (ACS-JPS) webinar to present a data from this study and AI drug development.
16 Mar 2023 According to a Hepion Pharmaceuticals media release, data from this study was used to design ongoing phase 2b ASCEND-NASH trial.
08 Nov 2022 Results of multi-omics analysis presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com